Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's Abeta Peptide.
The inhibition of angiogenesis is regarded as a promising avenue for cancer treatment. Although some antiangiogenic compounds are in the process of development and testing, these often prove ineffective in vivo, therefore the search for new inhibitors is critical. We have recently identified a ten amino acid fragment of the Alzheimer Abeta peptide that is anti-angiogenic both in vitro and in vivo. In the present study, we investigated the antitumoral potential of this decapeptide using human MCF-7 breast carcinoma xenografts nude mice. We observed that this decapeptide was able to suppress MCF-7 tumor growth more potently than the antiestrogen tamoxifen. Inhibition of tumor vascularization as determined by PECAM-1 immunostaining and decreased tumor cell proliferation as determined by Ki67 immunostaining were observed following treatment with the Abeta fragment. In vitro, this peptide had no direct impact on MCF-7 tumor cell proliferation and survival suggesting that the inhibition of tumor growth and tumor cell proliferation observed in vivo is related to the antiangiogenic activity of the peptide. Taken together these data suggest that this short Abeta derivative peptide may constitute a new antitumoral agent.
Paris
Daniel
D
The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA.
Patel
Nikunj
N
Ganey
Nowell J
NJ
Laporte
Vincent
V
Quadros
Amita
A
Mullan
Michael J
MJ
Neurol Res. 2003 Sep;25(6):642-51
14503019
AJNR Am J Neuroradiol. 2007 Apr;28(4):731-6
17416830
Trends Neurosci. 2005 Apr;28(4):202-8
15808355
Angiogenesis. 2004;7(1):75-85
15302999
Neurobiol Aging. 2008 Jan;29(1):1-11
17055615
Neurology. 2005 Mar 8;64(5):895-8
15753432
Curr Alzheimer Res. 2007 Apr;4(2):191-7
17430246
Lancet. 1992 Jan 11;339(8785):71-85
1345869
Neurol Res. 2005 Dec;27(8):869-81
16354549
Neurosci Lett. 2007 Nov 27;428(2-3):53-8
17964720
J Clin Pathol. 2004 Jul;57(7):675-81
15220356
Pharmacol Rev. 2001 Mar;53(1):25-71
11171938
J Am Geriatr Soc. 1999 Feb;47(2):189-95
9988290
Cell Death Differ. 2006 Jul;13(7):1088-96
16410806
J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
16288118
J Am Geriatr Soc. 1992 Oct;40(10):1075
1401685
J Am Geriatr Soc. 1991 Aug;39(8):840
2071819
Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12
17245412
J Natl Cancer Inst. 1995 May 3;87(9):645-51
7752269
Arch Neurol. 2005 May;62(5):779-84
15883266
Mech Ageing Dev. 2009 Jan-Feb;130(1-2):98-104
18452970
J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
17228000
Nat Med. 2005 Sep;11(9):959-65
16116430
J Alzheimers Dis. 2007 Mar;11(1):33-44
17361033
Neurosci Lett. 2004 Aug 5;366(1):80-5
15265595
Amyloid. 2008 Mar;15(1):5-19
18266117
Neurology. 2008 Jul 8;71(2):85-92
18509095
Exp Cell Res. 2009 Feb 1;315(3):385-95
19061884
J Endocrinol. 1979 Dec;83(3):401-8
536670
Endocrinology. 2007 Mar;148(3):1171-80
17138652
Brain Res Mol Brain Res. 2005 May 20;136(1-2):212-30
15893605
Mol Med. 2009 Mar-Apr;15(3-4):95-100
19081767
Breast Cancer Res Treat. 1998;51(3):227-38
10068081
Baillieres Clin Endocrinol Metab. 1990 Mar;4(1):67-84
1975167
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3587-92
18305170